secwatch.observer — SEC 8-K summary
======================================

Issuer:     HeartSciences Inc. (HSCS)
CIK:        0001468492
Form:       8-K
Filed at:   2025-03-13T23:59:59+00:00
Accession:  0000950170-25-038762
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

HeartSciences Q3 FY2025 no revenue, cash $2.6M; FDA submission for MyoVista device expected H1 2025
--------------------------------------------------------------------------------

- No revenue for Q3 FY2025; cash and equivalents $2.6M, shareholders' equity $1.8M as of Jan 31, 2025.
- Final pre-submission meeting with FDA for MyoVista wavECG device completed Feb 2025; clinical validation within weeks, FDA submission targeted H1 2025.
- MyoVista Insights cloud platform Phase 1 completed Dec 2024; Phase 2 (AI-ECG reporting, subject to FDA clearance) targets submission H2 2025.
- Pre-validation work commenced with Rutgers on low ejection fraction algorithm licensed from Mount Sinai; aim for FDA submission H2 2025.
- CMS 2025 OPPS final rule includes AI-ECG reimbursement effective Jan 2025, enabling reimbursement upon commercial launch.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1468492/000095017025038762/0000950170-25-038762-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1468492/000095017025038762/hscs-20250313.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-038762

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer